

REAL-WORLD PERFORMANCE OF THE MINIMED 780G ADVANCED HYBRID CLOSED LOOP AUTOMATED INSULIN DELIVERY SYSTEM IN GREECE


SUPPLEMENTARY MATERIALS

Authors: Vaia Lambadiari,¹ Nikolaos Tentolouris,² Andriani Vazeou,³ Athanasios Christoforidis,⁴ Christina Kanaka-Gantenbein,⁵ Konstantinos Makrilakis,² Triantafyllos Didangelos,⁴ Maria-Joanna Juachon,⁶ Vittorino Smaniotto,⁶ Tim van den Heuvel,⁶ Goran Petrovski⁶

Affiliations ¹ Diabetes Research Unit, The Second Propaedeutic Internal Medicine Department, Attikon University General Hospital, Athens, Greece.
² The First Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
³ Department of Pediatrics, Kyriakou Children's Hospital, Athens, Greece.
⁴ The First Department of Pediatrics, Aristotle University of Thessaloniki, Thessaloniki, Greece.
⁵ Division of Endocrinology, Diabetes and Metabolism, National and Kapodistrian University of Athens, Athens, Greece.
⁶ Diabetes Operating Unit, Medtronic/MiniMed, Tolochenaz, Switzerland.


Corresponding author Tim van den Heuvel
Diabetes Operating Unit, Medtronic/MiniMed, Tolochenaz,
Switzerland.
tim.vandenheuvel@medtronic.com

Supplementary Figure S1. Mean percentage of times in ranges pre- and post-AHCL initiation



Abbreviation: AHCL, advanced hybrid closed loop.

Supplementary Figure S2. Percentage of real-world MiniMed780G system users that reach international targets pre- and post-initiation of AHCL



Abbreviations: AHCL, advanced hybrid closed loop; GMI, glucose management indicator; TA180, time above 180 mg/dL; TA250, time above 250 mg/dL; TB54, time below 54 mg/dL; TB70, time below 70 mg/dL; TIR, time in range; TITR, time in tight range.

Paler bars on the left of each pair represent pre-initiation values while the darker bars on the right represent post-initiation values.

Supplementary Table S1. Glycemic control parameters of the pre- and post-AHCL cohort

	Overall cohort		≤15 years		16–55 years	
	Pre-AHCL	Post-AHCL	Pre-AHCL	Post-AHCL	Pre-AHCL	Post-AHCL
Users	1,234	1,234	324	324	801	801
SG, mg/dL	159±22	148±15.4	158±19.4	148±14	160±23.2	148±16.3
CV, %	34.2±5.1	33.5±4.5	35.5±4.9	35.1±4.5	33.9±5.1	33.0±4.3
GMI, %	7.12±0.53	6.85±0.37	7.10±0.46	6.86±0.34	7.13±0.55	6.85±0.39
TIR, %	65.1±13.9	74.9±9.6	65.6±12.4	73.7±8.9	64.6±14.5	75.1±9.9
TITR, %	40.3±13.5	50.4±10.3	41.6±12.6	50.6±9.1	39.8±13.9	50.3±10.8
TB70, %	2.86±2.69	2.12±1.91	2.82±2.23	2.36±1.73	2.94±2.90	2.1±2.03
TB54, %	0.64±0.94	0.43±0.56	0.6±0.74	0.49±0.53	0.68±1.02	0.44±0.60
% of users with GMI <7%, TIR >70%	33.5	67.7	32.1	67.0	33.5	67.7
% of users with GMI <7%, TIR >70%, TB70 <4%	22.1	59.0	22.2	59.0	21.5	58.1
% of users with GMI <7%, TIR >70%, TB70 <4%, TB54 <1%	21.8	58.3	22.2	57.1	21.0	57.8
Median (IQR) sensor usage, days	20.9 (14.3–36.0)	277 (125–494)	22.9 (14.1–36.0)	372 (175–592)	20.2 (14.3–35.6)	250 (107–456)
Median (IQR) time on automatic mode, days	–	278 (120–502)	–	374 (181–604)	–	251 (105–462)
Basal %	49.5±14.4	41.9±7.6	45.4±13.3	38.8±5.5	50.9±14.3	43.0±8.0
Auto bolus %	–	17.7±6.9	–	18.3±6.1	–	17.6±7.1
TDD, U/day	38.1±21.6	46.4±23.3	31.2±20.3	40.7±21.3	40.9±21.7	48.9±23.7
ICR, g/U	12.1±6.8	11.2±5.4	14.6±9.9	12.8±6.8	11.2±5.1	10.5±4.7
Distinct ICRs, n/day	1.36±0.79	1.67±0.83	1.94±0.91	2.48±0.87	1.15±0.62	1.37±0.59

All values are mean±standard deviation unless otherwise indicated.

Abbreviations: AHCL, advanced hybrid closed-loop; CV, coefficient of variation; GMI, glucose management indicator; ICR, insulin-to-carbohydrate ratio; IQR, interquartile range; ROS, recommended optimal settings; SG, sensor glucose; TB54, time below 54 mg/dL; TB70, time below 70 mg/dL; TDD, total daily dose; TIR, time in range; TITR, time in tight range.